Literature DB >> 8799683

Zollinger-Ellison syndrome. Recognition and management of acid hypersecretion.

P N Maton1.   

Abstract

Zollinger-Ellison syndrome (ZES) should be suspected if a patient has severe peptic ulceration, ulcers and kidney stones, a family history of ulcers or endocrine diseases, watery diarrhoea or malabsorption with or without ulcers, or if hypergastrinaemia is found. Any patient in whom ZES is suspected, and certainly if diagnosed, should be given large doses of antisecretory medication immediately. This should never be stopped except under controlled conditions or unless acid outputs have been reduced surgically. Patients cannot be managed safely without measuring acid outputs. These should be lowered to < 10 mmol/h, or < 5 mmol/h in patients with a previous gastric resection or severe oesophageal disease. Acid secretion can be controlled acutely in 70% of patients with an infusion of ranitidine 1 mg/kg/h, while 4 mg/kg/h will control acid in all. The initial oral dosage of omeprazole or lansoprazole should be 60 mg/day. Doses should then be adjusted daily on the basis of acid outputs. Proton pump inhibitors in a dosage of 60 mg/day will control acid output in most patients and 60 mg every 12 hours will control acid output in all. Doses can then often be slowly and progressively reduced. A parietal cell vagotomy reduces acid secretion and reduces, but does not abolish, the need for antisecretory medication. In patients with multiple endocrine neoplasia type 1 and hyperparathyroidism, a parathyroidectomy that results in normocalcaemia will reduce acid secretion and drug requirements. A total gastrectomy is rarely if ever needed nowadays. Given the high degree of safety of gastric antisecretory medications versus the risks of acid hypersecretion in patients with ZES, the mistakes in management of acid hypersecretion that must be avoided are those of giving insufficient medication and not measuring acid secretory rates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799683     DOI: 10.2165/00003495-199652010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  54 in total

1.  THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES.

Authors:  E H ELLISON; S D WILSON
Journal:  Ann Surg       Date:  1964-09       Impact factor: 12.969

Review 2.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

Review 3.  Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  P N Maton; J D Gardner; R T Jensen
Journal:  Gastroenterol Clin North Am       Date:  1989-12       Impact factor: 3.806

Review 4.  Surgical management of the Zollinger-Ellison syndrome.

Authors:  P S Fox; J W Hofmann; S D Wilson; J J DeCosse
Journal:  Surg Clin North Am       Date:  1974-04       Impact factor: 2.741

5.  Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.

Authors:  J P Raufman; S M Collins; S J Pandol; L Y Korman; M J Collen; M J Cornelius; M K Feld; D M McCarthy; J D Gardner; R T Jensen
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

6.  [Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].

Authors:  M Mignon; S Hochlaf; S Forestier; P Ruszniewski; J Vatier; M Joubert-Collin
Journal:  Gastroenterol Clin Biol       Date:  1994

7.  Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease.

Authors:  B Annibale; L De Magistris; V Corleto; G D'Ambra; M Marignani; C Iannoni; G Delle Fave
Journal:  Aliment Pharmacol Ther       Date:  1994-02       Impact factor: 8.171

Review 8.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management.

Authors:  M M Wolfe; R T Jensen
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

9.  Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study.

Authors:  J A Norton; M J Cornelius; J L Doppman; P N Maton; J D Gardner; R T Jensen
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

10.  Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.

Authors:  J C Delchier; J C Soule; M Mignon; D Goldfain; A Cortot; B Travers; J P Isal; J P Bader
Journal:  Dig Dis Sci       Date:  1986-07       Impact factor: 3.199

View more
  5 in total

1.  A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers.

Authors:  Sandy H Pang; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 2.  The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach.

Authors:  J R Pisegna
Journal:  Curr Gastroenterol Rep       Date:  1999-12

3.  Zollinger-Ellison Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

4.  Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.

Authors:  E A Lew; J R Pisegna; J A Starr; E F Soffer; C Forsmark; I M Modlin; J H Walsh; M Beg; W Bochenek; D C Metz
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

Review 5.  Gastrinoma.

Authors:  M L Li; J A Norton
Journal:  Curr Treat Options Oncol       Date:  2001-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.